Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma
Tebentafusp (IMCgp100) significantly improved overall survival in HLA-A*02:01-positive advanced uveal melanoma, establishing it as a first-line treatment.
Company
Pharmaceutical intelligence for Immunocore with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.